CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY - USD ($) shares in Thousands, $ in Thousands	Total	Common Shares	Treasury Stock	Capital in Excess of Par Value	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2022		188,560
Beginning balance at Dec. 31, 2022	$ 366,638	$ 19		$ 3,574,719	$ (6,907)	$ (3,201,193)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shares issued under equity compensation plans (in shares)		675
Stock-based compensation	10,019			10,019
Comprehensive income (loss)	(135,792)				1,226	(137,018)
Ending balance (in shares) at Mar. 31, 2023		189,235
Ending balance at Mar. 31, 2023	$ 240,865	$ 19		3,584,738	(5,681)	(3,338,211)
Beginning balance (in shares) at Dec. 31, 2023	191,384	191,384
Beginning balance at Dec. 31, 2023	$ 130,987	$ 19		3,608,137	80	(3,477,249)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shares issued under equity compensation plans (in shares)		525
Shares issued under equity compensation plans	3			3
Stock-based compensation	6,000			6,000
Repurchase of common stock from Bristol-Myers Squibb (in shares)		(8,285)	8,285
Repurchase of common stock from Bristol-Myers Squibb	(3,000)		$ (3,000)
Issuance of prefunded warrant	30,000			30,000
Comprehensive income (loss)	$ (37,285)				(483)	(36,802)
Ending balance (in shares) at Mar. 31, 2024	183,624	183,624	8,285
Ending balance at Mar. 31, 2024	$ 126,705	$ 19	$ (3,000)	$ 3,644,140	$ (403)	$ (3,514,051)